Back to top
more

Exelixis (EXEL)

(Delayed Data from NSDQ)

$37.46 USD

37.46
3,663,909

+0.65 (1.77%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $37.44 -0.02 (-0.05%) 4:42 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Endocyte (ECYT) to Post Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Endocyte, Inc (ECYT) is expected to report fourth-quarter 2016 results on Mar 1. The company has an impressive track record, having beaten estimates on three of the trailing four quarters and reporting in-line results in the remaining quarter

    Zacks Equity Research

    Horizon (HZNP) Q4 Earnings: Stock Likely to Disappoint?

    by Zacks Equity Research

    Horizon Pharma plc (HZNP) is scheduled to report fourth-quarter 2016 results on Feb 27, before the opening bell.

      Zacks Equity Research

      ACADIA Pharma (ACAD) Q4 Earnings: What's in Store this Time?

      by Zacks Equity Research

      ACADIA Pharmaceuticals Inc. (ACAD) is expected to report fourth-quarter 2016 results on Feb 28.

        Zacks Equity Research

        TriMas (TRS) to Post Q4 Earnings: What's in the Cards?

        by Zacks Equity Research

        TriMas Corporation (TRS) is scheduled to report fourth-quarter 2014 results on Feb 28, before the opening bell.

          Zacks Equity Research

          Juno Therapeutics (JUNO) Q4 Earnings: What's in the Cards?

          by Zacks Equity Research

          Juno Therapeutics Inc. (JUNO) is set to report fourth-quarter 2016 results on Mar 1, after the market closes.

            Zacks Equity Research

            Jazz Pharma (JAZZ) Q4 Earnings: Is a Surprise in Store?

            by Zacks Equity Research

            Jazz Pharmaceuticals plc (JAZZ) is scheduled to report fourth-quarter 2016 results on Feb 28 after the market closes.

              Zacks Equity Research

              Endo (ENDP) to Post Q4 Earnings: Will the Stock Disappoint?

              by Zacks Equity Research

              Endo International plc (ENDP) is scheduled to report fourth-quarter 2016 results on Feb 28, before the opening bell.

                Zacks Equity Research

                Exelixis (EXEL) Q4 Earnings: Is Positive Surprise in Store?

                by Zacks Equity Research

                Exelixis, Inc. (EXEL) is scheduled to report fourth-quarter 2016 results on Feb 27, after the market close.

                  Zacks Equity Research

                  Can Penumbra (PEN) Spring a Surprise this Earnings Season?

                  by Zacks Equity Research

                  Penumbra Inc. (PEN) is slated to release fourth-quarter 2016 results on Feb 28, after market close.

                    Zacks Equity Research

                    Intercept (ICPT) to Post Q4 Earnings: What's in the Cards?

                    by Zacks Equity Research

                    Intercept Pharmaceuticals, Inc. (ICPT) is scheduled to report fourth-quarter 2016 results on Feb 23.

                      Zacks Equity Research

                      Ionis (IONS) Q4 Earnings: What's in the Cards for the Stock?

                      by Zacks Equity Research

                      Ionis Pharmaceuticals, Inc. (IONS) is scheduled to report fourth-quarter 2016 results on Feb 28.

                        Zacks Equity Research

                        Patterson Companies (PDCO) Q3 Earnings: What's in Store?

                        by Zacks Equity Research

                        Patterson Companies Inc. (PDCO) is set to report fiscal third-quarter 2017 results on Feb 23, before the opening bell.

                          Arpita Dutt headshot

                          Forget Alexion, Buy these 4 Biotech Stocks Instead

                          by Arpita Dutt

                          We advise investors to consider biotech stocks which sport a strong Zacks Rank and have interesting pipelines/products and growth potential.

                            Zacks Equity Research

                            Medtronic (MDT) Q3 Earnings: Disappointment in the Cards?

                            by Zacks Equity Research

                            Ireland-based medical device major Medtronic plc (MDT) is slated to report its third-quarter fiscal 2017 earnings on Feb 21, before the opening bell.

                              Zacks Equity Research

                              Merrimack (MACK): What Awaits the Stock in Q4 Earnings?

                              by Zacks Equity Research

                              Merrimack Pharmaceuticals, Inc. (MACK) is scheduled to report fourth-quarter 2016 results in the next week. Last quarter, Merrimack delivered a positive earnings surprise of 23.33%.

                                Zacks Equity Research

                                Radius Health (RDUS) Q4 Earnings: Will the Stock Disappoint?

                                by Zacks Equity Research

                                Radius Health, Inc. (RDUS) is scheduled to report fourth-quarter 2016 financial results on Feb 23.

                                  Zacks Equity Research

                                  BioMarin (BMRN) Q4 Earnings: Will it Post a Beat Again?

                                  by Zacks Equity Research

                                  We expect BioMarin Pharmaceutical Inc. (BMRN) to beat expectations when it reports fourth-quarter and full-year 2016 results on Feb 23

                                    Zacks Equity Research

                                    The Zacks Analyst Blog Highlights: Gilead Sciences, Celgene, Fate Therapeutics, Exelixis and Akebia Therapeutics

                                    by Zacks Equity Research

                                    The Zacks Analyst Blog Highlights: Gilead Sciences, Celgene, Fate Therapeutics, Exelixis and Akebia Therapeutics

                                      Arpita Dutt headshot

                                      Forget Gilead, Buy These 5 Biotech Stocks Instead

                                      by Arpita Dutt

                                      With Gilead (GILD) providing a not-so-rosy outlook for 2017 as its HCV franchise continues to face challenges, here's a look at 5 biotech stocks that look better-positioned.

                                        Zacks Equity Research

                                        ITT Inc. (ITT) Q4 Earnings: What's in Store for the Stock?

                                        by Zacks Equity Research

                                        ITT Inc. (ITT) is slated to report fourth-quarter 2016 results before the opening bell on Feb 14.

                                          Zacks Equity Research

                                          Can Allscripts (MDRX) Surprise Investors in Q4 Earnings?

                                          by Zacks Equity Research

                                          Allscripts Healthcare Solutions Inc. (MDRX) is scheduled to release fourth-quarter 2016 results on Feb 16.

                                            Zacks Equity Research

                                            Zacks.com featured highlights: Exelixis, RPC, Unit and Fortress Transportation and Infrastructure Investors

                                            by Zacks Equity Research

                                            Zacks.com featured highlights: Exelixis, RPC, Unit and Fortress Transportation and Infrastructure Investors

                                              Zacks Equity Research

                                              Exelixis (EXEL) Shares March Higher, Can It Continue?

                                              by Zacks Equity Research

                                              As of late, it has definitely been a great time to be an investor in Exelixis, Inc. (EXEL).

                                                Zacks Equity Research

                                                Can Nutrisystem (NTRI) Surprise Investors in Q4 Earnings?

                                                by Zacks Equity Research

                                                Nutrisystem Inc. (NTRI) is scheduled to release fourth-quarter 2016 results on Feb 27.

                                                  Zacks Equity Research

                                                  Ecolab (ECL): What's in the Cards this Earnings Season?

                                                  by Zacks Equity Research

                                                  St. Paul, MN-based Ecolab Inc. (ECL), a leading provider of water, hygiene and energy technologies and services, is expected to report fourth-quarter 2016 results on Feb 21.